Emerging role of immunotherapy in locally advanced non-small cell lung cancer

Ria Mulherkar; Amardeep S. Grewal; Abigail T. Berman

Emerging role of immunotherapy in locally advanced non-small cell lung cancer

Ria Mulherkar, Amardeep S. Grewal, Abigail T. Berman

Radiation Oncology

University of Pennsylvania

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Non-small cell lung cancer (NSCLC) accounts for 85% of the cases of lung cancer in the United States, and 70% of patients with NSCLC have locally advanced or metastatic disease at the time of diagnosis. The 5-year overall survival rate for patients with locally advanced NSCLC is 15% to 20%. The traditional treatment paradigm for unresectable locally advanced NSCLC consists of platinum-based chemotherapy with concurrent radiation. Evidence from phase 3 clinical trials has established a role for immunotherapy after chemoradiation, and emerging data continue to elucidate the expanding role of immunotherapy.

Original language	English
Pages (from-to)	212-217
Number of pages	6
Journal	Clinical Advances in Hematology and Oncology
Volume	18
Issue number	4
State	Published - Apr 2020

Keywords

Carcinoma, Non-Small-Cell Lung/mortality
Chemoradiotherapy
Clinical Trials, Phase III as Topic
Disease-Free Survival
Humans
Immunotherapy
Lung Neoplasms/mortality
Survival Rate
United States/epidemiology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{1aab9a72e2c249fababb4923338f91d3,

title = "Emerging role of immunotherapy in locally advanced non-small cell lung cancer",

abstract = "Non-small cell lung cancer (NSCLC) accounts for 85% of the cases of lung cancer in the United States, and 70% of patients with NSCLC have locally advanced or metastatic disease at the time of diagnosis. The 5-year overall survival rate for patients with locally advanced NSCLC is 15% to 20%. The traditional treatment paradigm for unresectable locally advanced NSCLC consists of platinum-based chemotherapy with concurrent radiation. Evidence from phase 3 clinical trials has established a role for immunotherapy after chemoradiation, and emerging data continue to elucidate the expanding role of immunotherapy.",

keywords = "Carcinoma, Non-Small-Cell Lung/mortality, Chemoradiotherapy, Clinical Trials, Phase III as Topic, Disease-Free Survival, Humans, Immunotherapy, Lung Neoplasms/mortality, Survival Rate, United States/epidemiology",

author = "Ria Mulherkar and Grewal, {Amardeep S.} and Berman, {Abigail T.}",

year = "2020",

month = apr,

language = "English",

volume = "18",

pages = "212--217",

journal = "Clinical Advances in Hematology and Oncology",

issn = "1543-0790",

publisher = "Millennium Medical Publishing, Inc.",

number = "4",

}

TY - JOUR

T1 - Emerging role of immunotherapy in locally advanced non-small cell lung cancer

AU - Mulherkar, Ria

AU - Grewal, Amardeep S.

AU - Berman, Abigail T.

PY - 2020/4

Y1 - 2020/4

N2 - Non-small cell lung cancer (NSCLC) accounts for 85% of the cases of lung cancer in the United States, and 70% of patients with NSCLC have locally advanced or metastatic disease at the time of diagnosis. The 5-year overall survival rate for patients with locally advanced NSCLC is 15% to 20%. The traditional treatment paradigm for unresectable locally advanced NSCLC consists of platinum-based chemotherapy with concurrent radiation. Evidence from phase 3 clinical trials has established a role for immunotherapy after chemoradiation, and emerging data continue to elucidate the expanding role of immunotherapy.

AB - Non-small cell lung cancer (NSCLC) accounts for 85% of the cases of lung cancer in the United States, and 70% of patients with NSCLC have locally advanced or metastatic disease at the time of diagnosis. The 5-year overall survival rate for patients with locally advanced NSCLC is 15% to 20%. The traditional treatment paradigm for unresectable locally advanced NSCLC consists of platinum-based chemotherapy with concurrent radiation. Evidence from phase 3 clinical trials has established a role for immunotherapy after chemoradiation, and emerging data continue to elucidate the expanding role of immunotherapy.

KW - Carcinoma, Non-Small-Cell Lung/mortality

KW - Chemoradiotherapy

KW - Clinical Trials, Phase III as Topic

KW - Disease-Free Survival

KW - Humans

KW - Immunotherapy

KW - Lung Neoplasms/mortality

KW - Survival Rate

KW - United States/epidemiology

UR - http://www.scopus.com/inward/record.url?scp=85083674063&partnerID=8YFLogxK

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000523364200009&DestLinkType=FullRecord&DestApp=WOS

M3 - Article

C2 - 32628649

SN - 1543-0790

VL - 18

SP - 212

EP - 217

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

IS - 4

ER -

Emerging role of immunotherapy in locally advanced non-small cell lung cancer

Abstract

Keywords

UN SDGs

Other files and links

Fingerprint

Cite this